A new clinical trial published in the Chinese Medical Journal has assessed a novel triple-combination regimen comprising the angiogenesis inhibitors famitinib, the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor dalpiciclib, and fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer. Although the regimen exhibited measurable antitumor activity, its overall efficacy and safety profile did not support its use as a preferred first-line therapeutic option. 

HER2-positive breast cancer accounts for about 15% of all breast cancers, and although anti-HER2 targeted therapies have dramatically improved patient survival, primary and acquired drug resistance remain major clinical challenges. In a comprehensive review, researchers from Fudan University Shanghai Cancer Center, Kunming Medical University, and collaborating institutions map ten major categories of resistance mechanisms, evaluate strategies to overcome them—including next-generation antibody-drug conjugates—and highlight predictive tools that are paving the way toward precision treatment.

 

Triple-negative breast cancer (TNBC) remains one of the most challenging forms of breast cancer to treat because it lacks the estrogen, progesterone and HER2 receptors that enable targeted treatment in other breast cancer subtypes. A review published in Genes & Diseases examines how targeting the epidermal growth factor receptor (EGFR) alongside other molecular targets, supported by nanocarrier-based delivery, could offer new possibilities for more precise TNBC treatment.